Maintenance Olaparib Boosted Survival by 1 Year in Relapsed BRCA-Related Ovarian Cancer
Olaparib should be new standard for maintenance in these patients.
Ovarian Cancer
Lynparza Plus Bevacizumab Approved for First-Line Maintenance in HRD-Positive Advanced Ovarian Cancer
The FDA has approved Lynparza® for use in combination with bevacizumab as first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer
Ovarian Cancer Treatment Regimens
Access a detailed treatment regimen chart for ovarian cancer, with a focus on primary chemotherapy/primary adjuvant therapy with IV and IP options.
Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date
[OncoTargets and Therapy] In this review, researchers summarize use, indications, and clinical safety and efficacy of olaparib, a PARP inhibitor, in the treatment of ovarian cancer, including in patients with BRCA mutations.
New Research Says There’s No Significant Link Between Talc and Ovarian Cancer, but Some Scientists Push Back Against the Study’s Data and Design
Some experts say the talc study’s data limitations weaken its impact in the field.
Fertility-Sparing Surgery Achieves Good Oncologic, Obstetric Outcomes in Younger Women With Early-Stage Nonepithelial Ovarian Cancer
In this first reported prospective study, researchers compared outcomes of fertility-sparing surgery with radical surgery in women with stage I nonepithelial ovarian cancer.
Addition of Maintenance Olaparib Slows Advanced Ovarian Cancer
Benefit substantial for homologous-recombination deficiency positive tumors with, without BRCA mutations.
CA125 Can Detect Ovarian Cancer in General Practice
And elevated CA125 indicates higher risk for other cancers, especially in women aged ≥50 years.
Managing Anemia Associated With Olaparib for Relapsed Ovarian Cancer
What are the recommendations for managing anemia in patients receiving olaparib?
Zejula Approved for Late-line Treatment of Recurrent Ovarian Cancer
Zejula, a poly(ADP-ribose) polymerase (PARP) inhibitor, is also approved for maintenance treatment in adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Next post in Ovarian Cancer
